Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a the researchers launched a multicenter, prospective, single arm phase II clinical
study, the group always had at least two cycle line standard platinum-based treatment and
curative effect for SD, at least 6 months during or after the treatment of disease
progression broad stage small cell lung cancer patients, evaluating the efficacy and safety
of fluzopalil combination With anlotinib. Fifty patients are expected to be enrolled in this
study.